Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619587 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 410
- Enrollment target
- 20
- Study locations
NCT06619587: Recruiting Phase 1 study of Solid Tumor, sponsored by Genentech.
NCT06619587 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Genentech. The registered enrollment target is 410 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619587, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 410 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Conditions Studied
Interventions
- DRUG Phase I Arm A
- DRUG Phase I Arm B
Study Locations (20)
Other
- Rambam Health Care Campus - Haifa
- Hadassah University Hospital - Ein Kerem - Jerusalem
- The Chaim Sheba Medical Center - Ramat Gan
- Tel Aviv Sourasky Medical Center PPDS - Tel Aviv
Pennsylvania
- Mary Crowley Medical Research Center - Dallas
- Abramson Cancer Center;Univ of Pennsylvania - Philadelphia
California
- UC San Diego Moores Cancer Center - La Jolla
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Florida Cancer Specialist-Lake Mary - Lake Mary
Illinois
- University of Illinois - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 1 |
What NCT06619587 shows while recruiting
NCT06619587 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% higher).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Phase I Arm A is the first listed.
NCT06619587 names 20 study sites across 16 states, led by Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT06619587 about?
NCT06619587 is a clinical study titled "A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors". This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic ...
What is the current status of trial NCT06619587?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 410 participants. The study started on 2024-11-14. Estimated completion is 2028-05-31.
What conditions does trial NCT06619587 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06619587?
The interventions under investigation include: Phase I Arm A (DRUG), Phase I Arm B (DRUG).
Who is sponsoring clinical trial NCT06619587?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619587 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06619587's enrollment target sits among peer trials
410 11th of 196 higher than 186 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI